Quanterix Corporation, a company specializing in ultrasensitive biomarker detection, has announced a research license agreement with Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The agreement aims to enable research use availability of a Janssen proprietary assay for tau species containing phosphorylation at residues 217 and 212 (p217+ tau). Phosphorylated tau is a biomarker associated with Alzheimer’s disease pathology.
